Peer-Reviewed Study: bioAffinity Technologies’ CyPath® Lung Test Shows Potential Significant Healthcare Savings by Reducing Unnecessary Follow-Up, Medical Complications and Overdiagnosis
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Business Wire
Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancer SAN ANTONIO, Texas--(BUSINESS WIRE)--A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care for Medicare patients with a positive lung cancer screening could have saved an average of $2,773 per patient for total cost savings of $379 million in 2022. The peer-reviewed study, “Economic Evaluation of a Novel Lung Cancer Diagnostic in a Population of Patients with a Positive Low-Dose Computed Tomography Result,” attributes the savings to a reduction in follow-up diagnostic assessments, expensive follow-up procedures and procedure-related complications.Michael J. Morris, M.D., Brooke Army Medical Center (BAMC) pulmonology and critical care physician and Assistant Dean of Research at San Antonio Uniformed Services Health Educat
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024 [Yahoo! Finance]Yahoo! Finance
- bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024Business Wire
- bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product DevelopmentBusiness Wire
- U.S. Testing Laboratories, Safety and Compliance Services Industry Report 2024: Market Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2030 [Yahoo! Finance]Yahoo! Finance
- bioAffinity Technologies Announces Award of Japanese Patent for CyPath® LungBusiness Wire
BIAF
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 11/13/24 - Form PRE
- BIAF's page on the SEC website